Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies

Introduction: Studies assessing immune responses following Pfizer-BioNTech BNT162b2 mRNA COVID-19 (Pfizer) and ChAdOx1 nCoV-19 AZD1222 (AstraZeneca) vaccines in patients with hemoglobinopathy are non-existent in the literature despite being thought at high risk of infection. Methods: Prospectively,...

Descripción completa

Detalles Bibliográficos
Autores principales: Radhwi, Osman O., Jan, Hamza, Waheeb, Abdullah, Alamri, Sawsan S., Alahwal, Hatem M., Denetiu, Iuliana, Almanzlawey, Ashgan, Al-Marzouki, Adel F., Almohammadi, Abdullah T., Bahashwan, Salem M., Barefah, Ahmed S., Qari, Mohamad H., Abuzenadah, Adel M., Hashem, Anwar M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877446/
https://www.ncbi.nlm.nih.gov/pubmed/35214610
http://dx.doi.org/10.3390/vaccines10020151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877446/
https://www.ncbi.nlm.nih.gov/pubmed/35214610
http://dx.doi.org/10.3390/vaccines10020151

Ejemplares similares